These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11502968)

  • 1. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis.
    Papatheodoridis GV; Davies S; Dhillon AP; Teixeira R; Goulis J; Davidson B; Rolles K; Dusheiko G; Burroughs AK
    Transplantation; 2001 Aug; 72(3):412-8. PubMed ID: 11502968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P; Samonakis D; Cholongitas E; Patch D; O'Beirne J; Dhillon AP; Rolles K; McCormick A; Hayes P; Burroughs AK
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens.
    Papatheodoridis GV; Barton SG; Andrew D; Clewley G; Davies S; Dhillon AP; Dusheiko G; Davidson B; Rolles K; Burroughs AK
    Gut; 1999 Sep; 45(3):427-34. PubMed ID: 10446114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
    Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation.
    Samonakis DN; Triantos CK; Thalheimer U; Quaglia A; Leandro G; Teixeira R; Papatheodoridis GV; Sabin CA; Rolando N; Davies S; Dhillon AP; Griffiths P; Emery V; Patch DW; Davidson BR; Rolles K; Burroughs AK
    Liver Transpl; 2005 Apr; 11(4):386-95. PubMed ID: 15776454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes.
    Manousou P; Cholongitas E; Samonakis D; Tsochatzis E; Corbani A; Dhillon AP; Davidson J; Rodríguez-Perálvarez M; Patch D; O'Beirne J; Thorburn D; Luong T; Rolles K; Davidson B; McCormick PA; Hayes P; Burroughs AK
    Gut; 2014 Jun; 63(6):1005-13. PubMed ID: 24131637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.
    Delladetsima JK; Boletis JN; Makris F; Psichogiou M; Kostakis A; Hatzakis A
    Liver Transpl Surg; 1999 Jul; 5(4):294-300. PubMed ID: 10388502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: correlation with clinicopathological features.
    Rostaing L; Izopet J; Cisterne JM; Arnaud C; Duffaut M; Rumeau JL; Puel J; Durand D
    Transplantation; 1998 Apr; 65(7):930-6. PubMed ID: 9565097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P; Busuttil RW; Goldstein RM; Crippin JS; Klintmalm GB; Fitzsimmons WE; Uleman C
    Liver Transpl; 2004 Oct; 10(10):1258-62. PubMed ID: 15376310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.
    Manzia TM; Angelico R; Ciano P; Mugweru J; Owusu K; Sforza D; Toti L; Tisone G
    World J Gastroenterol; 2014 Sep; 20(34):12217-25. PubMed ID: 25232255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of recurrent hepatitis C after liver transplantation.
    Teixeira R; Papatheodoridis GV; Burroughs AK
    J Viral Hepat; 2001 May; 8(3):159-68. PubMed ID: 11380792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis.
    Wietzke-Braun P; Braun F; Sattler B; Ramadori G; Ringe B
    World J Gastroenterol; 2004 Aug; 10(15):2213-7. PubMed ID: 15259068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis.
    Samonakis DN; Mela M; Quaglia A; Triantos CK; Thalheimer U; Leandro G; Pesci A; Raimondo ML; Dhillon AP; Rolles K; Davidson BR; Patch DW; Burroughs AK
    Transpl Infect Dis; 2006 Mar; 8(1):3-12. PubMed ID: 16623815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.
    Manousou P; Burroughs AK; Tsochatzis E; Isgro G; Hall A; Green A; Calvaruso V; Ma GL; Gale J; Burgess G; O'Beirne J; Patch D; Thorburn D; Leandro G; Dhillon AP
    J Hepatol; 2013 May; 58(5):962-8. PubMed ID: 23262247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of sirolimus on hepatitis C recurrence after liver transplantation.
    Asthana S; Toso C; Meeberg G; Bigam DL; Mason A; Shapiro J; Kneteman NM
    Can J Gastroenterol; 2011 Jan; 25(1):28-34. PubMed ID: 21258665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of hepatitis C infection after liver transplantation.
    Gane EJ; Portmann BC; Naoumov NV; Smith HM; Underhill JA; Donaldson PT; Maertens G; Williams R
    N Engl J Med; 1996 Mar; 334(13):815-20. PubMed ID: 8596547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.